Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

386886

	registered interest
	date	01/07/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Amyloidosis and Multiple Myeloma
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government whether they will place in the Library of the House any publications resulting from the phase 3 clinical trials approved for the potential treatment of systemic amyloidosis or multiple myeloma; and what is the National Institute of Health Research’s assessment of progress in these areas.
	tabling member printed	Lord Willis of Knaresborough
	uin	HL995
	answer	answer is ministerial correction date of answer 14/07/2015 answer text <p>There are four trials for systemic amyloidosis that are designated as ‘ongoing’ in the United Kingdom. These are being conducted by two commercial sponsors, Millennium Pharmaceuticals Inc and A.T. Development Switzerland Sarl (two studies), and one non-commercial sponsor, European Myeloma Network.</p><p> </p><p> </p><p> </p><p>Clinical trial sponsors are required to publish a summary of their trial results to the EU Clinical Trials Register within one year of their trial completing. At that point, these results will become publically available on the EU Clinical Trials Register</p><p> </p><p> </p><p> </p><p>The Department of Health, which funds the National Institute for Health Research (NIHR), is a member of the National Cancer Research Institute (NCRI). NCRI Clinical Studies Groups (CSGs) bring together clinicians, scientists, statisticians and lay representatives to coordinate development of a strategic portfolio of trials within their field. All CSGs interact with clinical research networks, funders (including NIHR) and researchers to develop studies aimed at improving outcomes for patients. The Haematological Oncology CSG has a Myeloma Subgroup and its 2013-14 annual report that includes an assessment of progress in these areas is attached and available on the NCRI website at:</p><p> </p><p><a href="http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf" target="_blank">http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf</a>.</p><p> </p><p> </p><p> </p><p>We cannot comment on commercial considerations. When the results are known, the commercial potential of these trial’s products will be a matter for the respective trial sponsors.</p><p> </p> answering member printed Lord Prior of Brampton grouped question UIN HL996 HL997 question first answered 14/07/2015 15:34:29 answering member 127 label Biography information for Lord Prior of Brampton attachment 1 file name NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf title 2013-14 Annual Report
	tabling member	4151 label Biography information for Lord Willis of Knaresborough

386887

	registered interest
	date	01/07/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Amyloidosis
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government whether there are currently any trials for systemic amyloidosis in humans being conducted by the National Institute of Health Research charities or the commercial sector.
	tabling member printed	Lord Willis of Knaresborough
	uin	HL996
	answer	answer is ministerial correction date of answer 14/07/2015 answer text <p>There are four trials for systemic amyloidosis that are designated as ‘ongoing’ in the United Kingdom. These are being conducted by two commercial sponsors, Millennium Pharmaceuticals Inc and A.T. Development Switzerland Sarl (two studies), and one non-commercial sponsor, European Myeloma Network.</p><p> </p><p> </p><p> </p><p>Clinical trial sponsors are required to publish a summary of their trial results to the EU Clinical Trials Register within one year of their trial completing. At that point, these results will become publically available on the EU Clinical Trials Register</p><p> </p><p> </p><p> </p><p>The Department of Health, which funds the National Institute for Health Research (NIHR), is a member of the National Cancer Research Institute (NCRI). NCRI Clinical Studies Groups (CSGs) bring together clinicians, scientists, statisticians and lay representatives to coordinate development of a strategic portfolio of trials within their field. All CSGs interact with clinical research networks, funders (including NIHR) and researchers to develop studies aimed at improving outcomes for patients. The Haematological Oncology CSG has a Myeloma Subgroup and its 2013-14 annual report that includes an assessment of progress in these areas is attached and available on the NCRI website at:</p><p> </p><p><a href="http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf" target="_blank">http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf</a>.</p><p> </p><p> </p><p> </p><p>We cannot comment on commercial considerations. When the results are known, the commercial potential of these trial’s products will be a matter for the respective trial sponsors.</p><p> </p> answering member printed Lord Prior of Brampton grouped question UIN HL995 HL997 question first answered 14/07/2015 15:34:29 answering member 127 label Biography information for Lord Prior of Brampton attachment 1 file name NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf title 2013-14 Annual Report
	tabling member	4151 label Biography information for Lord Willis of Knaresborough

386888

	registered interest
	date	01/07/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Amyloidosis
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government which of the four phase 2 or 3 clinical trials for systemic amyloidosis approved since 2004 are still ongoing; and whether any of the trials have produced sufficient positive outcomes to encourage commercial development.
	tabling member printed	Lord Willis of Knaresborough
	uin	HL997
	answer	answer is ministerial correction date of answer 14/07/2015 answer text <p>There are four trials for systemic amyloidosis that are designated as ‘ongoing’ in the United Kingdom. These are being conducted by two commercial sponsors, Millennium Pharmaceuticals Inc and A.T. Development Switzerland Sarl (two studies), and one non-commercial sponsor, European Myeloma Network.</p><p> </p><p> </p><p> </p><p>Clinical trial sponsors are required to publish a summary of their trial results to the EU Clinical Trials Register within one year of their trial completing. At that point, these results will become publically available on the EU Clinical Trials Register</p><p> </p><p> </p><p> </p><p>The Department of Health, which funds the National Institute for Health Research (NIHR), is a member of the National Cancer Research Institute (NCRI). NCRI Clinical Studies Groups (CSGs) bring together clinicians, scientists, statisticians and lay representatives to coordinate development of a strategic portfolio of trials within their field. All CSGs interact with clinical research networks, funders (including NIHR) and researchers to develop studies aimed at improving outcomes for patients. The Haematological Oncology CSG has a Myeloma Subgroup and its 2013-14 annual report that includes an assessment of progress in these areas is attached and available on the NCRI website at:</p><p> </p><p><a href="http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf" target="_blank">http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf</a>.</p><p> </p><p> </p><p> </p><p>We cannot comment on commercial considerations. When the results are known, the commercial potential of these trial’s products will be a matter for the respective trial sponsors.</p><p> </p> answering member printed Lord Prior of Brampton grouped question UIN HL995 HL996 question first answered 14/07/2015 15:34:29 answering member 127 label Biography information for Lord Prior of Brampton attachment 1 file name NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf title 2013-14 Annual Report
	tabling member	4151 label Biography information for Lord Willis of Knaresborough

386467

	registered interest
	date	30/06/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Pancreatic Cancer: Nurses
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what steps they are taking to ensure that all pancreatic cancer patients have access to a clinical nurse specialist.
	tabling member printed	Lord Aberdare
	uin	HL962
	answer	answer is ministerial correction date of answer 09/07/2015 answer text <p>NHS England has a published service specification for pancreatic cancer which clearly defines what it expects to be in place for providers to offer evidence-based, safe and effective pancreatic cancer services. This service specification has been developed by specialised clinicians, commissioners, expert patients and public health representatives to describe core and developmental service standards.</p><p> </p><p> </p><p> </p><p>Patients being treated at cancer units should have access to an upper gastrointestinal cancer nurse. All district general hospitals should have such a person in post. If the patient is transferred to a cancer centre they should then have access to a pancreatic nurse specialist. This person should see every patient and become their key worker.</p><p> </p><p> </p><p> </p><p>Patients with suspected pancreatic cancer are usually first investigated by an ultrasound scan. If this shows biliary dilatation, or anything else suspicious, the patient should then be sent for a pancreas protocol computerised tomography scan which is the best investigation for identifying pancreatic cancer.</p><p> </p><p> </p><p> </p><p>Increasing the capacity of diagnostic and imaging services is clearly recognised as a priority for the National Health Service and it is has been raised as a key issue by the independent Cancer Taskforce, as well as by the Cancer Waiting Times Taskforce. We expect a new cancer strategy to be published this summer which will set out the strategy for the system for the next five years and will include consideration of the whole cancer pathway, including the capacity of diagnostic services.</p><p> </p><p> </p><p> </p><p>In addition, NHS England is testing various approaches to new models of care which could potentially deliver improved access to diagnostic services for cancer patients, including those with pancreatic cancer.</p><p> </p> answering member printed Lord Prior of Brampton grouped question UIN HL963 question first answered 09/07/2015 12:43:47 answering member 127 label Biography information for Lord Prior of Brampton
	tabling member	3898 label Biography information for Lord Aberdare

386468

	registered interest
	date	30/06/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Pancreatic Cancer: Tomography
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what plans they have to increase the capacity of imaging services available to pancreatic cancer patients across the National Health Service, including computerised tomography scans.
	tabling member printed	Lord Aberdare
	uin	HL963
	answer	answer is ministerial correction date of answer 09/07/2015 answer text <p>NHS England has a published service specification for pancreatic cancer which clearly defines what it expects to be in place for providers to offer evidence-based, safe and effective pancreatic cancer services. This service specification has been developed by specialised clinicians, commissioners, expert patients and public health representatives to describe core and developmental service standards.</p><p> </p><p> </p><p> </p><p>Patients being treated at cancer units should have access to an upper gastrointestinal cancer nurse. All district general hospitals should have such a person in post. If the patient is transferred to a cancer centre they should then have access to a pancreatic nurse specialist. This person should see every patient and become their key worker.</p><p> </p><p> </p><p> </p><p>Patients with suspected pancreatic cancer are usually first investigated by an ultrasound scan. If this shows biliary dilatation, or anything else suspicious, the patient should then be sent for a pancreas protocol computerised tomography scan which is the best investigation for identifying pancreatic cancer.</p><p> </p><p> </p><p> </p><p>Increasing the capacity of diagnostic and imaging services is clearly recognised as a priority for the National Health Service and it is has been raised as a key issue by the independent Cancer Taskforce, as well as by the Cancer Waiting Times Taskforce. We expect a new cancer strategy to be published this summer which will set out the strategy for the system for the next five years and will include consideration of the whole cancer pathway, including the capacity of diagnostic services.</p><p> </p><p> </p><p> </p><p>In addition, NHS England is testing various approaches to new models of care which could potentially deliver improved access to diagnostic services for cancer patients, including those with pancreatic cancer.</p><p> </p> answering member printed Lord Prior of Brampton grouped question UIN HL962 question first answered 09/07/2015 12:43:47 answering member 127 label Biography information for Lord Prior of Brampton
	tabling member	3898 label Biography information for Lord Aberdare

76618

	registered interest
	date	09/07/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Neurofibromatosis
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what plans they have to develop a national service framework for neurofibromatosis Type 1 sufferers.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL960
	answer	answer is ministerial correction date of answer 14/07/2014 answer text <p>The number of people with neurofibromatosis type 1 (NF1) in England is estimated to number 11,267. The condition can be mild in some patients, manifesting itself only in patches of skin discolouration and soft benign bumps under the skin (neurofibromas), but for others NF1 causes more serious complications, including a rare form of cancer, curvature of the spine and nerve problems caused by more invasive neurofibromas.</p><p> </p><p>Since 1 April 2013, NHS England has been responsible for securing high quality care for all patients with complex NF1 as part of its specialised commissioning responsibilities. NHS England's NF1 service specification clearly sets out what needs to be in place for providers to offer evidence-based, safe and effective care, ensuring equity of access to a nationally consistent, high quality service. Specialist care is delivered by two designated centres based in Manchester (Central Manchester University Hospitals NHS Foundation Trust) and London (Guys and St. Thomas' NHS Foundation Trust, London) and these provide outreach support into other cities. The service is available to all patients with a suspected or confirmed diagnosis of NF1.</p><p> </p><p>The service specification can be viewed on the NHS England website at the following link:</p><p> </p><p>www.england.nhs.uk/wp-content/uploads/2013/06/b13-comp-neurofib-1.pdf.</p> answering member printed Earl Howe grouped question UIN HL961 HL962 question first answered 14/07/2014 16:18:37 answering member 2000 label Biography information for Earl Howe
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

76619

	registered interest
	date	09/07/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Neurofibromatosis
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government how they will ensure a co-ordinated response at local level for neurofibromatosis Type 1 sufferers.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL961
	answer	answer is ministerial correction date of answer 14/07/2014 answer text <p>The number of people with neurofibromatosis type 1 (NF1) in England is estimated to number 11,267. The condition can be mild in some patients, manifesting itself only in patches of skin discolouration and soft benign bumps under the skin (neurofibromas), but for others NF1 causes more serious complications, including a rare form of cancer, curvature of the spine and nerve problems caused by more invasive neurofibromas.</p><p> </p><p>Since 1 April 2013, NHS England has been responsible for securing high quality care for all patients with complex NF1 as part of its specialised commissioning responsibilities. NHS England's NF1 service specification clearly sets out what needs to be in place for providers to offer evidence-based, safe and effective care, ensuring equity of access to a nationally consistent, high quality service. Specialist care is delivered by two designated centres based in Manchester (Central Manchester University Hospitals NHS Foundation Trust) and London (Guys and St. Thomas' NHS Foundation Trust, London) and these provide outreach support into other cities. The service is available to all patients with a suspected or confirmed diagnosis of NF1.</p><p> </p><p>The service specification can be viewed on the NHS England website at the following link:</p><p> </p><p>www.england.nhs.uk/wp-content/uploads/2013/06/b13-comp-neurofib-1.pdf.</p> answering member printed Earl Howe grouped question UIN HL960 HL962 question first answered 14/07/2014 16:18:38 answering member 2000 label Biography information for Earl Howe
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

76620

	registered interest
	date	09/07/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Neurofibromatosis
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what is the scale of neurofibromatosis Type 1 in the United Kingdom.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL962
	answer	answer is ministerial correction date of answer 14/07/2014 answer text <p>The number of people with neurofibromatosis type 1 (NF1) in England is estimated to number 11,267. The condition can be mild in some patients, manifesting itself only in patches of skin discolouration and soft benign bumps under the skin (neurofibromas), but for others NF1 causes more serious complications, including a rare form of cancer, curvature of the spine and nerve problems caused by more invasive neurofibromas.</p><p> </p><p>Since 1 April 2013, NHS England has been responsible for securing high quality care for all patients with complex NF1 as part of its specialised commissioning responsibilities. NHS England's NF1 service specification clearly sets out what needs to be in place for providers to offer evidence-based, safe and effective care, ensuring equity of access to a nationally consistent, high quality service. Specialist care is delivered by two designated centres based in Manchester (Central Manchester University Hospitals NHS Foundation Trust) and London (Guys and St. Thomas' NHS Foundation Trust, London) and these provide outreach support into other cities. The service is available to all patients with a suspected or confirmed diagnosis of NF1.</p><p> </p><p>The service specification can be viewed on the NHS England website at the following link:</p><p> </p><p>www.england.nhs.uk/wp-content/uploads/2013/06/b13-comp-neurofib-1.pdf.</p> answering member printed Earl Howe grouped question UIN HL960 HL961 question first answered 14/07/2014 16:18:38 answering member 2000 label Biography information for Earl Howe
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

347226

	registered interest
	date	28/05/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Clinical Commissioning Groups: Staffordshire
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what assessment they have made of the conclusion drawn in the Staffordshire Distressed Health Economy report by KPMG that there is a lack of collaborative working across the six Clinical Commissioning Groups in Staffordshire to maximise leadership capabilities.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL90
	answer	answer is ministerial correction date of answer 09/06/2015 answer text <p>NHS England has identified the Staffordshire clinical commissioning groups (CCGs) as high risk, and as such is monitoring their performance on a monthly basis with a full quarterly review of finance and performance. NHS England increases the intensity of performance reviews where there are significant shortfalls. This includes weekly meetings with CCGs where appropriate.</p><p> </p><p> </p><p> </p><p>Collaborative working relationships are a critical factor in securing sustainable services in any local health economy. The Commissioning Congress has been set up in Staffordshire to bring together both CCGs and local authority commissioners. The Congress will lead the Transformation Strategy which will drive the service redesign of the Staffordshire Health and Social Care economy to secure financial and clinically sustainable services in the long term. The Congress will engage with local providers in developing these plans to ensure that there is a single five-year plan for the local health economy. This work will lead to a full public consultation on those services during the autumn of 2015.</p><p> </p><p> </p><p> </p><p> </p><p> </p><p>The Congress brings together the combined skills, knowledge and expertise of commissioners to work the provider sector on defining the range, scale and scope of services changes to ensure Staffordshire is both clinically and financially sustainable in the long term.</p><p> </p> answering member printed Lord Prior of Brampton grouped question UIN HL88 HL91 HL92 HL93 question first answered 09/06/2015 12:42:46 answering member 127 label Biography information for Lord Prior of Brampton
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

347224

	registered interest
	date	28/05/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Health Services: Staffordshire
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what action they are taking to ensure the viability of comprehensive patient services in the Staffordshire local health economy.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL88
	answer	answer is ministerial correction date of answer 09/06/2015 answer text <p>NHS England has identified the Staffordshire clinical commissioning groups (CCGs) as high risk, and as such is monitoring their performance on a monthly basis with a full quarterly review of finance and performance. NHS England increases the intensity of performance reviews where there are significant shortfalls. This includes weekly meetings with CCGs where appropriate.</p><p> </p><p> </p><p> </p><p>Collaborative working relationships are a critical factor in securing sustainable services in any local health economy. The Commissioning Congress has been set up in Staffordshire to bring together both CCGs and local authority commissioners. The Congress will lead the Transformation Strategy which will drive the service redesign of the Staffordshire Health and Social Care economy to secure financial and clinically sustainable services in the long term. The Congress will engage with local providers in developing these plans to ensure that there is a single five-year plan for the local health economy. This work will lead to a full public consultation on those services during the autumn of 2015.</p><p> </p><p> </p><p> </p><p> </p><p> </p><p>The Congress brings together the combined skills, knowledge and expertise of commissioners to work the provider sector on defining the range, scale and scope of services changes to ensure Staffordshire is both clinically and financially sustainable in the long term.</p><p> </p> answering member printed Lord Prior of Brampton grouped question UIN HL90 HL91 HL92 HL93 question first answered 09/06/2015 12:42:46 answering member 127 label Biography information for Lord Prior of Brampton
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath